Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting, 33343 [2024-09080]
Download as PDF
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 83 / Monday, April 29, 2024 / Notices
Vice President at Pennsylvania State
University, will provide a classified
briefing on semiconductor
manufacturing. Next, DSB Members will
deliberate and vote on the DSB Task
Force to Advise Implementation and
Prioritization of National Security
Innovation Activities executive
summary; the DSB Task Force on Digital
Engineering Capability to Automate
Testing and Evaluation report/executive
summary; and the DSB 2024 Summer
Study on Climate Change and Global
Security report/executive summary.
Following break, Dr. William LaPlante,
Under Secretary for Acquisition and
Sustainment (A&S), will provide a
classified briefing on his views of
current A&S strategy, challenges, and
priorities. Finally, DSB members will
have a classified plenary discussion
regarding briefer remarks and ongoing
studies. The meeting will adjourn at
3:30 p.m.
Meeting Accessibility: In accordance
with 5 U.S.C. 1009(d) and 41 CFR 102–
3.155, the DoD has determined that the
DSB meeting will be closed to the
public. Specifically, the USD(R&E), in
consultation with the DoD Office of the
General Counsel, has determined in
writing that the meeting will be closed
to the public because it will consider
matters covered by 5 U.S.C. 552b(c)(1).
The determination is based on the
consideration that it is expected that
discussions throughout will involve
classified matters of national security
concern. Such classified material is so
intertwined with the unclassified
material that it cannot reasonably be
segregated into separate discussions
without defeating the effectiveness and
meaning of the overall meetings. To
permit the meeting to be open to the
public would preclude discussion of
such matters and would greatly
diminish the ultimate utility of the
DSB’s findings and recommendations to
the Secretary of Defense and to the
USD(R&E).
Written Statements: In accordance
with 5 U.S.C. 1009(a)(3) and 41 CFR
102–3.105(j) and 102–3.140, interested
persons may submit a written statement
for consideration by the DSB at any time
regarding its mission or in response to
the stated agenda of a planned meeting.
Individuals submitting a written
statement must submit their statement
to the DSB DFO at the email address
provided in the FOR FURTHER
INFORMATION CONTACT section at any
point; however, if a written statement is
not received at least three calendar days
prior to the meeting, which is the
subject of this notice, then it may not be
provided to or considered by the DSB
until a later date.
VerDate Sep<11>2014
20:54 Apr 26, 2024
Jkt 262001
Dated: April 23, 2024.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
[FR Doc. 2024–09088 Filed 4–26–24; 8:45 am]
BILLING CODE 6001–FR–P
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary
Advisory Panel; Notice of Federal
Advisory Committee Meeting
Under Secretary of Defense for
Personnel and Readiness (USD(P&R)),
Department of Defense (DoD).
ACTION: Notice of Federal advisory
committee meeting.
AGENCY:
The DoD is publishing this
notice to announce that the following
Federal Advisory Committee meeting of
the Uniform Formulary Beneficiary
Advisory Panel (UFBAP) will take
place.
DATES: Open to the public Wednesday,
June 26, 2024, from 10:00 a.m. to 1:00
p.m. Eastern Standard Time.
ADDRESSES: The meeting will be held
telephonically or via conference call.
The phone number for the remote access
on June 26, 2024, is: CONUS: 1–888–
831–4306; OCONUS: 1–210–234–8694;
PARTICIPANT CODE: 9136304.
These numbers and the dial-in
instructions will also be posted on the
UFBAP website at: https://
www.health.mil/Military-Health-Topics/
Access-Cost-Quality-and-Safety/
Pharmacy-Operations/BAP.
FOR FURTHER INFORMATION CONTACT:
Designated Federal Official (DFO)
Captain Tiffany F. Cline, USN, 703–
681–2890 (voice), dha.ncr.j6.mbx.baprequests@health.mil (email).
Mailing address is 7700 Arlington
Boulevard, Suite 5101, Falls Church, VA
22042–5101. Website: https://
www.health.mil/Military-Health-Topics/
Access-Cost-Quality-and-Safety/
Pharmacy-Operations/BAP. The most
up-to-date changes to the meeting
agenda can be found on the website.
SUPPLEMENTARY INFORMATION: This
meeting is being held under the
provisions of chapter 10 of title 5,
United States Code (U.S.C.) (commonly
known as ‘‘the Federal Advisory
Committee Act’’ or ‘‘FACA’’), 5 U.S.C.
552b (commonly known as the
‘‘Government in the Sunshine Act’’),
and 41 CFR 102–3.140 and 102–3.150.
Purpose of the Meeting: The UFBAP
will review and comment on
recommendations made by the
Pharmacy and Therapeutics Committee
SUMMARY:
PO 00000
Frm 00032
Fmt 4703
Sfmt 9990
33343
to the Director, Defense Health Agency
regarding the Uniform Formulary.
Agenda:
1. 10:00 a.m.–10:10 a.m. Sign in for
UFBAP members
2. 10:10 a.m.–10:40 a.m. Welcome and
Opening Remarks
a. Welcome, Opening Remarks, and
Introduction of UFBAP Members by
CAPT Tiffany F. Cline, DFO,
UFBAP
b. Public Written Comments by CAPT
Tiffany F. Cline, DFO, UFBAP
c. Opening Remarks by Dr. Pamela
Schweitzer, UFBAP Chair
d. Introductory Remarks by Dr.
Edward Vonberg, Chief, Formulary
Management Branch
3. 10:40 a.m.–11:45 a.m. Scheduled
Therapeutic Class Reviews
4. 11:45 a.m.–12:30 p.m. Newly
Approved Drugs Review
5. 12:30 p.m.–12:45 p.m. Pertinent
Utilization Management Issues
6. 12:45 p.m.–1:00 p.m. Closing remarks
a. Closing Remarks by UFBAP CoChair
b. Closing Remarks by DFO, UFBAP
Meeting Accessibility: Pursuant to 5
U.S.C. 1009(a)(1) and 41 CFR 102–3.140
through 102–3.165, and subject to the
availability of phone lines, this meeting
is open to the public. Telephone lines
are limited and available to the first 220
people dialing in. There will be 220
lines total: 200 domestic and 20
international, including leader lines.
Written Statements: Pursuant to 41
CFR 102–3.105(j) and 102–3.140(c), and
5 U.S.C. 1009(a)(3), interested persons
or organizations may submit written
statements to the UFBAP about its
mission and/or the agenda to be
addressed in this public meeting.
Written statements should be submitted
to the UFBAP’s DFO. The DFO’s contact
information can be found in the FOR
FURTHER INFORMATION CONTACT section of
this notice. Written comments or
statements must be received by the
UFBAP’s DFO at least five (5) calendar
days prior to the meeting so they may
be made available to the UFBAP for its
consideration prior to the meeting.
Written comments received are
releasable to the public. The DFO will
review all submitted written statements
and provide copies to UFBAP.
Dated: April 23, 2024.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
[FR Doc. 2024–09080 Filed 4–26–24; 8:45 am]
BILLING CODE 6001–FR–P
E:\FR\FM\29APN1.SGM
29APN1
Agencies
[Federal Register Volume 89, Number 83 (Monday, April 29, 2024)]
[Notices]
[Page 33343]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09080]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee Meeting
AGENCY: Under Secretary of Defense for Personnel and Readiness
(USD(P&R)), Department of Defense (DoD).
ACTION: Notice of Federal advisory committee meeting.
-----------------------------------------------------------------------
SUMMARY: The DoD is publishing this notice to announce that the
following Federal Advisory Committee meeting of the Uniform Formulary
Beneficiary Advisory Panel (UFBAP) will take place.
DATES: Open to the public Wednesday, June 26, 2024, from 10:00 a.m. to
1:00 p.m. Eastern Standard Time.
ADDRESSES: The meeting will be held telephonically or via conference
call. The phone number for the remote access on June 26, 2024, is:
CONUS: 1-888-831-4306; OCONUS: 1-210-234-8694; PARTICIPANT CODE:
9136304.
These numbers and the dial-in instructions will also be posted on
the UFBAP website at: https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP.
FOR FURTHER INFORMATION CONTACT: Designated Federal Official (DFO)
Captain Tiffany F. Cline, USN, 703-681-2890 (voice), [email protected] (email). Mailing address is 7700 Arlington
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP. The most up-to-date changes to the meeting
agenda can be found on the website.
SUPPLEMENTARY INFORMATION: This meeting is being held under the
provisions of chapter 10 of title 5, United States Code (U.S.C.)
(commonly known as ``the Federal Advisory Committee Act'' or ``FACA''),
5 U.S.C. 552b (commonly known as the ``Government in the Sunshine
Act''), and 41 CFR 102-3.140 and 102-3.150.
Purpose of the Meeting: The UFBAP will review and comment on
recommendations made by the Pharmacy and Therapeutics Committee to the
Director, Defense Health Agency regarding the Uniform Formulary.
Agenda:
1. 10:00 a.m.-10:10 a.m. Sign in for UFBAP members
2. 10:10 a.m.-10:40 a.m. Welcome and Opening Remarks
a. Welcome, Opening Remarks, and Introduction of UFBAP Members by
CAPT Tiffany F. Cline, DFO, UFBAP
b. Public Written Comments by CAPT Tiffany F. Cline, DFO, UFBAP
c. Opening Remarks by Dr. Pamela Schweitzer, UFBAP Chair
d. Introductory Remarks by Dr. Edward Vonberg, Chief, Formulary
Management Branch
3. 10:40 a.m.-11:45 a.m. Scheduled Therapeutic Class Reviews
4. 11:45 a.m.-12:30 p.m. Newly Approved Drugs Review
5. 12:30 p.m.-12:45 p.m. Pertinent Utilization Management Issues
6. 12:45 p.m.-1:00 p.m. Closing remarks
a. Closing Remarks by UFBAP Co-Chair
b. Closing Remarks by DFO, UFBAP
Meeting Accessibility: Pursuant to 5 U.S.C. 1009(a)(1) and 41 CFR
102-3.140 through 102-3.165, and subject to the availability of phone
lines, this meeting is open to the public. Telephone lines are limited
and available to the first 220 people dialing in. There will be 220
lines total: 200 domestic and 20 international, including leader lines.
Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-
3.140(c), and 5 U.S.C. 1009(a)(3), interested persons or organizations
may submit written statements to the UFBAP about its mission and/or the
agenda to be addressed in this public meeting. Written statements
should be submitted to the UFBAP's DFO. The DFO's contact information
can be found in the FOR FURTHER INFORMATION CONTACT section of this
notice. Written comments or statements must be received by the UFBAP's
DFO at least five (5) calendar days prior to the meeting so they may be
made available to the UFBAP for its consideration prior to the meeting.
Written comments received are releasable to the public. The DFO will
review all submitted written statements and provide copies to UFBAP.
Dated: April 23, 2024.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2024-09080 Filed 4-26-24; 8:45 am]
BILLING CODE 6001-FR-P